Nymox Pharmaceutical (NASDAQ: NYMX) and New England Nuclear (NASDAQ:LNTH) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, risk, dividends, analyst recommendations and institutional ownership.
Valuation & Earnings
This table compares Nymox Pharmaceutical and New England Nuclear’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Nymox Pharmaceutical||$220,000.00||1,050.58||-$13.10 million||N/A||N/A|
|New England Nuclear||$331.38 million||1.75||$123.38 million||$1.00||15.35|
Insider & Institutional Ownership
6.4% of Nymox Pharmaceutical shares are owned by institutional investors. Comparatively, 90.5% of New England Nuclear shares are owned by institutional investors. 54.0% of Nymox Pharmaceutical shares are owned by insiders. Comparatively, 1.2% of New England Nuclear shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
This table compares Nymox Pharmaceutical and New England Nuclear’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|New England Nuclear||37.23%||-68.13%||14.00%|
Volatility & Risk
Nymox Pharmaceutical has a beta of 0.73, suggesting that its share price is 27% less volatile than the S&P 500. Comparatively, New England Nuclear has a beta of 1.52, suggesting that its share price is 52% more volatile than the S&P 500.
This is a summary of current recommendations and price targets for Nymox Pharmaceutical and New England Nuclear, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|New England Nuclear||0||1||3||0||2.75|
New England Nuclear has a consensus price target of $24.00, indicating a potential upside of 56.35%. Given New England Nuclear’s higher probable upside, analysts plainly believe New England Nuclear is more favorable than Nymox Pharmaceutical.
New England Nuclear beats Nymox Pharmaceutical on 8 of the 11 factors compared between the two stocks.
Nymox Pharmaceutical Company Profile
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population. It markets NicAlert and TobacAlert test strips that use urine or saliva to detect use of tobacco products. The company also offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is in Phase III clinical trials for the treatment of enlarged prostate or benign prostatic hyperplasia, as well as is in Phase II clinical trial for low grade localized prostate cancer. The company markets its products in Canada, the United States, Europe, and internationally. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, The Bahamas.
New England Nuclear Company Profile
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, an ultrasound contrast agent used in ultrasound exams of the heart; TechneLite, a technetium generator that provides the essential nuclear material used in nuclear medicine procedures; and Xenon, a radiopharmaceutical gas used to assess pulmonary function and imaging cerebral blood flow. The company also offers Neurolite, an injectable that is used to identify the area in the brain where blood flow has been blocked or reduced due to stroke; and Cardiolite, an injectable technetium-labeled imaging agent used in myocardial perfusion imaging (MPI) procedures that assess blood flow distribution to the heart. In addition, it provides injectable radiopharmaceutical imaging agents, such as Thallium Tl 201 that is used in MPI studies to detect cardiovascular disease; Gallium Ga 67, which is used to detect various infections and cancerous tumors; FDG, a fluorine-18-radiolabeled imaging agent to identify and characterize tumors in patients undergoing oncologic diagnostic procedures; and Quadramet, a therapeutic product, which is used to treat severe bone pain associated with metastatic bone lesions. Further, the company is developing Flurpiridaz F 18, which is in Phase III clinical trials to assess blood flow to the heart; LMI 1195 that has completed Phase I clinical trials for assessing cardiac sympathetic nerve function; and LMI 1174, which is in pre-clinical development targeted to elastin in the arterial walls and atherosclerotic plaque. The company sells its products to hospitals, clinics, group practices, integrated delivery networks, group purchasing organizations, and radiopharmacies. Lantheus Holdings, Inc. was founded in 1956 and is headquartered in North Billerica, Massachusetts.
Receive News & Ratings for Nymox Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nymox Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.